European Journal of Nuclear Medicine

, Volume 22, Issue 7, pp 595–599 | Cite as

Imaging amyloidosis with radiolabelled SAP

  • P. N. Hawkins
  • M. B. Pepys
Editorial

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Husby G. Nomenclature and classification of amyloid and amyloidoses.J Intern Med 1992; 232: 511–512.PubMedGoogle Scholar
  2. 2.
    Pepys MB. Amyloidosis. In: Frank MM, Austen KF, Claman HN, Unaue ER, eds.Samter's immunologic diseases, 5th edn. Boston: Little, Brown and Company; 1994: 637–655.Google Scholar
  3. 3.
    Koch KM. Dialysis-related amyloidosis [clinical conference].Kidney Int 1992; 41: 1416–1429.PubMedGoogle Scholar
  4. 4.
    Pepys MB, Rademacher TW, Amatayakul-Chantler S, Williams P, Noble GE, Hutchinson WL, Hawkins PN, Nelson SR, Gallimore JR, Herbert J, Hutton T, Dwek RA. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure.Proc Natl Acad Sci USA 1994; 91: 5602–5606.PubMedGoogle Scholar
  5. 5.
    Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis.Proc Natl Acad Sci USA 1995;92:4299–4303.PubMedGoogle Scholar
  6. 6.
    Nelson SR, Tennent GA, Sethi D, Gower PE, Ballardie FW, Amatayakul-Chantler S, Pepys MB. Serum amyloid P component in chronic renal failure and dialysis.Clin Chim Acta 1991;200:191–200.PubMedGoogle Scholar
  7. 7.
    Hawkins PN, Wootton R, Pepys MB. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis.J Clin Invest 1990; 86:1862–1869.PubMedGoogle Scholar
  8. 8.
    Baltz ML, Gomer K, Davies AJS, Evans DJ, Klaus GGB, Pepys MB. Differences in the acute phase responses of serum amyloid P component (SAP) and C3 to injections of casein or bovine serum albumin in amyloid-susceptible and resistant mouse strains.Clin Exp Immunol 1980; 39: 355–360.PubMedGoogle Scholar
  9. 9.
    Baltz ML, Caspi D, Rowe IF, Hind CRK, Evans DJ, Pepys MB. Pathogenetic mechanisms and precursor product relationships in murine amyloidosis. In: Glenner GG, Osserman EF, Benditt EP, Calkins E, Cohen AS, Zucker-Franklin D, eds.Amyloidosis. New York: Plenum Press; 1986: 101–108.Google Scholar
  10. 10.
    Caspi D, Zalzman S, Baratz M, Teitelbaum Z, Yaron M, Pras M, Baltz ML, Pepys MB. Imaging of experimental amyloidosis with131I-serum amyloid P component.Arthritis Rheum 1987;30:1303–1306.PubMedGoogle Scholar
  11. 11.
    Hawkins PN, Tennent GA, Woo P, Pepys MB. Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis.Clin Exp Immunol 1991; 84: 308–316.PubMedGoogle Scholar
  12. 12.
    Hutchinson WL, Noble GE, Hawkins PN, Pepys MB. The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo.J Clin Invest 1994; 94:1390–1396.PubMedGoogle Scholar
  13. 13.
    Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with123I-labeled serum amyloid P component.N Engl J Med 1990; 323: 508–513.PubMedGoogle Scholar
  14. 14.
    Hawkins PN, Myers MJ, Epenetos AA, Caspi D, Pepys MB. Specific localization and imaging of amyloid deposits in vivo using123I-labeled serum amyloid P component.J Exp Med 1988;167:903–913.PubMedGoogle Scholar
  15. 15.
    Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease.J Clin Invest 1993; 91: 1351–1357.PubMedGoogle Scholar
  16. 16.
    Vigushin DM, Pepys MB, Hawkins PN. Comparison of histology with SAP scintigraphy for evaluation of amyloidosis. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID, eds.Amyloid and amyloidosis 1993. Pearl River, New York: Parthenon Publishing; 1994: 685–687.Google Scholar
  17. 17.
    Hawkins PN, Myers MJ, Lavender JP, Pepys MB. Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human amyloid P component.Lancet 1988; i: 1413–1418.Google Scholar
  18. 18.
    Hawkins PN. Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo.Clin Sci 1994; 87: 289–295.PubMedGoogle Scholar
  19. 19.
    Hawkins PN, Vigushin DM, Richardson S, Seymour A, Pepys MB. Evaluation of 100 cases in systemic. AL amyloidosis by serum amyloid P component (SAP) scintigraphy. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID, eds.Amyloid and amyloidosis 1993. Pearl River, New York: Parthenon Publishing; 1994: 209–211.Google Scholar
  20. 20.
    Hawkins PN, Richardson S, MacSweeney JE, King AD, Vigushin DM, Lavender JP, Pepys MB. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression.QJ Med 1993; 86:365–374.Google Scholar
  21. 21.
    Hawkins PN, Richardson S, Vigushin DM, David J, Kelsey CR, Gray RES, Hall MA, Woo P, Lavender JP, Pepys MB. Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis.Arthritis Rheum 1993; 36:842–851.PubMedGoogle Scholar
  22. 22.
    Tan SY, Pepys MB, Hawkins PN. Treatment of amyloidosis.Am J Kidney Dis. 1995; (in press).Google Scholar
  23. 23.
    Hawkins PN, Vigushin DM, Richardson S, Seymour A, Holmgren G, Steen L, Woo P, Hall A, Peters AM, Pepys MB. Natural history and regression of amyloidosis. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID, eds.Amyloid and amyloidosis 1993. Pearl River, New York: Parthenon Publishing; 1994: 638–641.Google Scholar
  24. 24.
    Hawkins PN, Hall M, Hall R, Penny L, Henderson A, Yacoub M, Mitchell A, Pepys MB. Regression of AL amyloidosis and prolonged survival following cardiac transplantation and chemotherapy. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID, eds.Amyloid and amyloidosis 1993. Pearl River, New York: Parthenon Publishing; 1994: 657–659.Google Scholar
  25. 25.
    Tan SY, Madhoo S, Brown E, Gower P, Irish A, Winearls C, Clutterbuck EJ, Pepys MB, Hawkins PN. Effect of renal transplantation on dialysis-related amyloid deposits: prospective evaluation by123I-SAP scintigraphy [abstract].Nephrol Dial Transplant 1994; 9:1017.Google Scholar
  26. 26.
    Holmgren G, Ericzon B-G, Groth C-G, Steen L, Suhr O, Andersen O, Wallin BG, Seymour A, Richardson S, Hawkins PN, Pepys MB. Clinical benefit and regression of amyloidosis following liver transplantation in patients with familial amyloid polyneuropathy due to transthyretin variant Met-30.Lancet 1993; 341: 1113–1116.PubMedGoogle Scholar
  27. 27.
    Hutchinson WL, Mather SJ, Staltieri M, Noble GE, Vigushin DM, Tan SY, Seymour A, Pepys MB, Hawkins PN. Scintigraphic imaging of amyloid deposits with99mTc-labelled serum amyloid P component. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID, eds.Amyloid and amyloidosis 1993. Pearl River, New York: Parthenon Publishing; 1994: 682–684.Google Scholar
  28. 28.
    Hawking PN, Tyrrell P, Jones T, Rossor MN, Roques P, Myers M, Lambrecht R, Richardson S, Gudmundsson G, Pepys MB. Metabolic and scintigraphic studies with radiolabeled serum amyloid P component in amyloidosis: applications to cerebral deposits and Alzheimer disease with positron emission tomography.Bull Clin Neurosci 1991: 56: 178–190.Google Scholar
  29. 29.
    Emsley J, White HE, O'Hara BP, Oliva G, Srinivasan N, Tickle IJ, Blundell TL, Pepys MB, Wood SP. Structure of pentameric human serum amyloid P component.Nature 1994; 367: 338–345.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • P. N. Hawkins
    • 1
  • M. B. Pepys
    • 1
  1. 1.Immunological Medicine Unit, Department of MedicineRoyal Postgraduate Medical SchoolLondonUK

Personalised recommendations